First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG)

• DOI: 10.1007/s00432-014-1661-z
• Publication Date: 2014-04-02T10:28:36Z
• Authors: Lars Arne Berger; Carsten Bokemeyer; Anja Lorch; Marcus Hentrich; Hans-Georg Kopp; Thomas Christoph ...; Jörg Beyer; Maike de Wit; Frank Mayer; Ina Boehlke; Christoph Oing; Friedemann Honecker; Karin Oechsle
• Keywords: Adult; Male; Adolescent; Medizin; 610; 610 Medicine & health; Young Adult; 03 medical and health sciences; 0302 clinical medicine; Testicular Neoplasms; Germany; Antineoplastic Combined Chemotherapy Protocols; Humans; 1306 Cancer Research; Registries; Retrospective Studies; Salvage Therapy; Dose-Response Relationship, Drug; Middle Aged; Neoplasms, Germ Cell and Embryonal; Survival Analysis; 3. Good health; Chemotherapy, Adjuvant; 10032 Clinic for Oncology and Hematology; 2730 Oncology; Cisplatin; Stem Cell Transplantation

We analyzed prognostic categories at first relapse according to the International Prognostic Factors Study Group (IPFSG) criteria as well as the efficacy of salvage treatment.143 patients with relapsed or refractory germ cell cancer undergoing first salvage treatment with conventional-dose (CD-CX, n = 48) or high-dose chemotherapy with autologous stem cell support (HD-CX, n = 95) contributed by nine centers were retrospectively analyzed.Prognostic subgroups according to IPFSG criteria were: very low risk 13/143, low risk 36/143, intermediate risk 66/143, high risk 22/143, and very high risk 6/143 patients. The IPFSG categories significantly correlated with overall survival (OS) (p = 0.025) after 1st salvage treatment. After a median follow-up of 19 months, 55 % of all patients had relapsed and 33 % had died. For the entire cohort, progression-free survival (PFS) rate after 2 years was 43 %, and OS rate after 5 years was 52 %. Compared to the HD-CX group, vital carcinoma was found more often in secondarily resected lesions following CD-CX (22/29 vs. 22/45; p = 0.021). Second relapse rate was higher with 75 versus 44 %, resulting in a shorter median PFS with 8 versus 42 months (p < 0.001), but this did not translate into different OS (p = 0.931). At subsequent relapses, 26/36 patients received HD-CX as ≥2nd-salvage treatment.This analysis confirms the prognostic value of the IPFSG prognostic score. HD-CX seemed superior to CD-CX as first salvage treatment with respect to PFS in this retrospective analysis.